In This Section

Research Funding Impact

Since 1993, the AACR has awarded more than $540 million in grants to fund meritorious research projects across the spectrum of cancer science, including basic, translational, and clinical research. See how the AACR grants program has contributed to the AACR's mission.

Loading...
Resistance to BETi in breast cancer: more than meets the eye

Resistance to BETi in breast cancer: more than meets the eye

ER+ breast cancer patients typically receive endocrine therapies targeting the estrogen receptor, but approximately half of high-grade diseases will likely progress, highlighting the urgent need for new and effective treatment options. Supported by a 2018 AACR-John and Elizabeth Leonard Family Foundation Basic Cancer Research Fellowship, Dr. Sicong Zhang, investigated why BET inhibitors (BETi), a promising class of anti-cancer drugs, have failed to show efficacy in clinical trials for ER+ breast cancer patients.

AACR Grantees Share their Findings

AACR Grantees Share their Findings

We are extremely proud of our past and present grantees who presented and published their findings throughout 2024. Their accomplishments have been made possible, thanks to the support of the AACR and its funding partners. JANUARY Tumor development in...

A One up in the Battle against Multiple Myeloma 

A One up in the Battle against Multiple Myeloma 

Despite the surge in new treatments, multiple myeloma remains stubbornly incurable. Patients typically respond to their first treatment for about two years, but subsequent therapies often provide diminishing relief due to overlapping mechanisms of action. This underscores the urgent need for novel therapeutic strategies rather than mere variations of existing ones. Amin Sobh, PhD, recipient of the 2019 AACR-Takeda Oncology Myeloma Research Fellowship, identified adenylate kinase 2 as a promising target, particularly for multiple myeloma patients with the t(4;14) chromosomal translocation.

A Closer Look at Global MGUS Disparity: One Size Does Not Fit All

A Closer Look at Global MGUS Disparity: One Size Does Not Fit All

Multiple myeloma disproportionately affects Black Americans, who are twice as likely to be diagnosed with it and its precursor, monoclonal gammopathy of undetermined significance (MGUS). Is this disparity related to ethnic ancestry or environmental factors? 2022 AACR-BMS Cancer Disparities Fellow Kara Cicero, MD and her international team observed that the prevalence of conventional MGUS was similar between Eswatini, a country in Africa where 97% of the population is Black, and Olmsted County in Minnesota where 97% of the population is White.

Diversifying Cancer Research with the Breast Cancer Research Foundation-AACR Career Development Award to Promote Diversity and Inclusion

Diversifying Cancer Research with the Breast Cancer Research Foundation-AACR Career Development Award to Promote Diversity and Inclusion

Despite having a lower incidence of breast cancer, Black women in the U.S. face a mortality rate that is higher than that of non-Hispanic White women. Investing in early-career researchers to promote diversity in cancer research and care is crucial for overcoming cancer disparities. Recipients of the Breast Cancer Research Foundation-AACR Career Development Awards to Promote Diversity and Inclusion share the impact of such investment.

Revolutionizing Uveal Melanoma Treatment: SCANDIUM-II Trial Combines Chemotherapy and Immunotherapy for Promising Results 

Revolutionizing Uveal Melanoma Treatment: SCANDIUM-II Trial Combines Chemotherapy and Immunotherapy for Promising Results 

Roger Olofsson Bagge, MD, PhD, recipient of the 2021 AACR-OMF Career Development Award, in honor of Robert C. Allen, MD, shares how the recent SCANDIUM-II clinical trial found that isolated hepatic perfusion with melphalan in combination with immunotherapies, ipilimumab and nivolumab was efficacious in the treatment of patients with liver-dominant metastases of uveal melanoma, but associated with severe adverse events.